Vycor Medical (OTCMKTS:VYCO – Get Free Report) and CVRx (NASDAQ:CVRX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.
Volatility and Risk
Vycor Medical has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, CVRx has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Insider & Institutional Ownership
75.3% of CVRx shares are owned by institutional investors. 7.0% of Vycor Medical shares are owned by company insiders. Comparatively, 18.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Vycor Medical | $1.46 million | 1.97 | -$70,000.00 | N/A | N/A |
CVRx | $44.39 million | 4.09 | -$41.20 million | ($2.47) | -3.40 |
Vycor Medical has higher earnings, but lower revenue than CVRx.
Profitability
This table compares Vycor Medical and CVRx’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Vycor Medical | -7.49% | N/A | -10.32% |
CVRx | -122.52% | -72.51% | -49.78% |
Analyst Ratings
This is a summary of recent ratings and target prices for Vycor Medical and CVRx, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Vycor Medical | 0 | 0 | 0 | 0 | N/A |
CVRx | 0 | 2 | 4 | 0 | 2.67 |
CVRx has a consensus price target of $13.60, indicating a potential upside of 61.90%. Given CVRx’s higher possible upside, analysts plainly believe CVRx is more favorable than Vycor Medical.
Summary
CVRx beats Vycor Medical on 7 of the 11 factors compared between the two stocks.
About Vycor Medical
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.
About CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Vycor Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vycor Medical and related companies with MarketBeat.com's FREE daily email newsletter.